<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602104</url>
  </required_header>
  <id_info>
    <org_study_id>MEXARDS</org_study_id>
    <nct_id>NCT04602104</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS</brief_title>
  <official_title>A Multiple, Randomized, Double-blinded, Controlled Clinical Study of Allogeneic Human Mesenchymal Stem Cell Exosomes (hMSC-Exos) Nebulized Inhalation in the Treatment of Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of&#xD;
      acute respiratory distress syndrome (ARDS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the 2012 Berlin diagnostic criteria, there are currently more than 3 million&#xD;
      ARDS patients worldwide, accounting for about 10% of patients in the intensive care unit&#xD;
      (ICU). In recent years, the incidence of ARDS has increased significantly, which has&#xD;
      significantly increased the social and economic burden. The impact of ARDS can even be&#xD;
      compared with tumors, AIDS or myocardial infarction. There are the basic clinical treatments,&#xD;
      such as using various ventilation methods to improve hypoxia and choosing alternative&#xD;
      therapies to improve renal insufficiency. Therefore, there is still a lack of specific&#xD;
      treatment measures.&#xD;
&#xD;
      Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers&#xD;
      with the abundance of adhesive proteins that readily interact with cellular membranes.&#xD;
      Studies have confirmed that MSC-Exos can improve most of the pathological changes caused by&#xD;
      lung infection, reduce pulmonary edema, reduce protein exudation, reduce alveolar&#xD;
      inflammation, and clear bacterial infections. Thus, it brings new hope for the treatment of&#xD;
      ARDS.&#xD;
&#xD;
      The purpose of this study is to evaluate allogeneic human mesenchymal stem cell exosomes&#xD;
      (hMSC-Exos) in the treatment of acute respiratory distress syndrome (ARDS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse reaction</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Incidence of adverse reaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TTCI</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Time to Clinical improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>up to 28 days</time_frame>
    <description>28-day mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Murray lung injury score</measure>
    <time_frame>baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60</time_frame>
    <description>The minimum value is 0 and the maximum are 16. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>baseline and Day 3, Day7, Day14, Day28, Day60</time_frame>
    <description>oxygen index: the ratio of alveolar oxygen partial pressure to fraction of inspired oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60</time_frame>
    <description>The minimum value is 0 and the maximum are 48. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apachâ…¡ score</measure>
    <time_frame>baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60</time_frame>
    <description>The minimum value is 0 and the maximum are 24. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days the survivor was in ICU</measure>
    <time_frame>up to 60 days</time_frame>
    <description>The number of days the survivor was in ICU</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Phase 1: hMSC-Exos low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hMSC-Exos low-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: hMSC-Exos medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hMSC-Exos medium-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: hMSC-Exos high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hMSC-Exos high-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: hMSC-Exos dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basic treatment+hMSC-Exos (a quarter of MTD/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: hMSC-Exos dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basic treatment+hMSC-Exos (MTD/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>basic treatment+normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>low dose hMSC-Exos</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 1: hMSC-Exos low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>medium dose hMSC-Exos</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 1: hMSC-Exos medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>high dose hMSC-Exos</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 1: hMSC-Exos high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dosage 1of hMSC-Exos</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 2: hMSC-Exos dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dosage 2 of hMSC-Exos</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 2: hMSC-Exos dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>No hMSC-derived exosomes</intervention_name>
    <description>basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)</description>
    <arm_group_label>Phase 2: control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects themselves or their family members voluntarily participate in this study&#xD;
             and sign the informed consent form;&#xD;
&#xD;
          2. 18-70 years old, male or female;&#xD;
&#xD;
          3. Definitely diagnosed as acute respiratory distress syndrome (ARDS) (according to the&#xD;
             Berlin definition and diagnostic criteria of ARDS);&#xD;
&#xD;
          4. Course of disease &lt;96 hours after diagnosis;&#xD;
&#xD;
          5. Chest X-ray showed bilateral infiltration with pulmonary edema; no clinical&#xD;
             manifestations of left ventricular hypertension, or pulmonary artery wedge pressure&#xD;
             (PAOP) â‰¤18mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe allergic constitution;&#xD;
&#xD;
          2. Moderate to severe liver failure (children Pugh score &gt; 12);&#xD;
&#xD;
          3. Patients with severe chronic respiratory diseases, PaCO2 &gt; 50mmhg, and need home&#xD;
             oxygen therapy;&#xD;
&#xD;
          4. Severe trauma occurred within 14 days before screening;&#xD;
&#xD;
          5. History of malignant tumor (patients with skin basal cell carcinoma in the past can be&#xD;
             included);&#xD;
&#xD;
          6. They are undergoing hemodialysis or peritoneal dialysis;&#xD;
&#xD;
          7. The patients who had deep venous thrombosis or pulmonary embolism within 90 days;&#xD;
&#xD;
          8. Acute myocardial infarction occurred within 30 days;&#xD;
&#xD;
          9. Neuromuscular diseases that result in impaired natural ventilation include, but are&#xD;
             not limited to, C5 or higher spinal cord injury, amyotrophic lateral sclerosis,&#xD;
             Guillain Barre syndrome, and myasthenia gravis;&#xD;
&#xD;
         10. Obesity (BMI &gt; 28);&#xD;
&#xD;
         11. Lung transplantation;&#xD;
&#xD;
         12. Bone marrow transplantation;&#xD;
&#xD;
         13. Active immunosuppression is defined as receiving immunosuppressive drugs or having a&#xD;
             medical condition associated with immunodeficiency. These included: 1) HIV (AIDS or&#xD;
             CD4 &lt; 200 cells / mm3); 2) chemotherapy within 6 weeks before randomization; 3)&#xD;
             immunosuppressive therapy, including maintenance glucocorticoid therapy (&gt; 40)&#xD;
             Results: 1) short term systemic steroid therapy (intravenous or oral) for less than 1&#xD;
             week, topical steroid for skin diseases; 4) absolute neutrophil count &lt; 500 / mm3;&#xD;
&#xD;
         14. Patients undergoing extracorporeal circulation support (ECMO) or high frequency&#xD;
             oscillatory ventilation;&#xD;
&#xD;
         15. They were not willing to receive lung protective ventilation (minimum tidal volume 6ml&#xD;
             / kg pbw) or liquid management treatment;&#xD;
&#xD;
         16. Have a history of epilepsy, need continuous anticonvulsant therapy, or have received&#xD;
             anticonvulsant therapy in the past 3 years;&#xD;
&#xD;
         17. The estimated survival time was less than 30 days;&#xD;
&#xD;
         18. Hepatitis B, hepatitis C, AIDS, syphilis patients;&#xD;
&#xD;
         19. Women of childbearing age are pregnant, lactating or pregnant within one year;&#xD;
&#xD;
         20. Those who could not understand the study protocol;&#xD;
&#xD;
         21. According to the judgment of the researchers, there were other situations in which the&#xD;
             patients were not suitable to participate in the study (for example, there were&#xD;
             factors to reduce the follow-up compliance, and the patients did not receive relevant&#xD;
             supportive treatment, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jieming Qu, MD, PhD</last_name>
    <phone>86-21-64370045</phone>
    <email>jmqu0906@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Medical School of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieming Qu, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <email>jmqu0906@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human mesenchymal stem cell exosomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data (IPD) available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

